<DOC>
	<DOCNO>NCT01291433</DOCNO>
	<brief_summary>Radiation-induced brachial plexopathy ( RIP ) rare severe delay peripheral nerve complication radiotherapy , spontaneously irreversible medical treatment limit reduce symptom . The investigator plan RIP randomize double blind clinical trial , use pentoxifylline ( P ) - tocopherol ( E ) - clodronate combination versus placebo , ass possible symptomatic regression sensory-motor neurological quantifiable reproducible score ( modify Subjective Objective Medical management Analytic , SOMA ) . The investigator previously develop successful PE treatment symptomatic RI injury via antioxidant pathway , clinical phase II III trail experiment obtain major significant radiation-induced fibrosis regression , PE clodronate combination ( PENTOCLO ) , obtain rapid significant heal mandible osteoradionecrosis significant neurological sign regression ( - 35 % modify SOMA score 18 month ) 50 partial RIP . The aim phase III randomize clinical trial show PENTOCLO efficiency tolerance long survival patient irradiated cancer present partial RIP upper low leg . The investigator calculate include 60 patient show significant clinical difference two group 18 month treatment : PENTOCLO [ Pentoxifylline 400 ( 2x/d ) + vitamine E 500 ( 2x/d ) + intermittent Clodronate 800 ( 2/d , 5d/7 ) ] versus triple placebo , prednisone 20 ( 2d/7 ) patient . RIP assess treatment every 6 month standardize sensory-motor neurological ( SOMA 95 modify NCI-CTC 99 ) score use main criterion M18 , various neurological scale assessment ( Visual Analog Scale pain / VAS paresthesia , Neuropathic Pain Symptom Inventory [ NPSI ] , Overall Disability Sum Score [ ODSS ] , muscle testing , Nine hole peg test / Timed 25-Foot Walk ) , quality life ( SF36 , Patient Global Impression Change Clinical Global impression Change [ PGIC/ CGIC ] ) electrophysiology .</brief_summary>
	<brief_title>Trial Combined Pentoxifylline-tocopherol-clodronate v Placebo Radiation-induced Brachial Plexopathy</brief_title>
	<detailed_description>The aim phase III randomize clinical trial show PENTOCLO efficiency tolerance long survival patient irradiated cancer present partial RIP upper low leg . We calculate include 60 patient show significant clinical difference two group 18 month treatment : PENTOCLO [ Pentoxifylline 400 ( 2x/d ) + vitamine E 500 ( 2x/d ) + intermittent Clodronate 800 ( 2/d , 5d/7 ) ] versus triple placebo , prednisone 20 ( 2d/7 ) patient . RIP assess treatment every 6 month standardize sensory-motor neurological ( SOMA 95 modify NCI-CTC 99 ) score use main criterion M18 , various neurological scale assessment ( Visual Analog Scale [ VAS ] pain / VAS paresthesia , Neuropathic Pain Symptom Inventory [ NPSI ] , Overall Disability Sum Score [ ODSS ] , muscle testing , Nine hole peg test / Timed 25-Foot Walk ) , quality life ( SF36 , Patient Global Impression Change Clinical Global impression Change [ PGIC/ CGIC ] ) electrophysiology .</detailed_description>
	<mesh_term>Brachial Plexus Neuropathies</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Clodronic Acid</mesh_term>
	<criteria>Pasthistory postoperative exclusive irradiation ( RT ) currently remission cancer , particular breast cancer breast thoracic anterior wall RT ; axillasubclavicular lymph node RT ; sometimes lung head/neck cancer Lymphoma ( Hodgkin non Hodgkin ) axillasubclavicular RT ( upper limb ) lumbaraortic ( low limb ) testis tumor Delay RTRIP 6 month , partial RIP Neurological injury irradiate volume confirm EMG Patient living within distance compatible dayhospitalization Use effective contraception fertile woman Signed write informed consent ( case motor paralysis inform consent sign witness ) Localized metastatic cancer recurrence ( axillar MRI PET scan ) Complete plexus injury total motor paralysis upper/ low limb 2 year Associated neurological disease may interferer assessment endpoint Hemorrhage , disease hemorrhagic risk , unbalanced diabetes Known hypersensitivity Pentoxifylline , one excipients biphosphonates Renal failure , liver failure decompensated heart failure Taking another biphosphonate Evolving virosis ( hepatitis , herpes , zona ) live vaccine ( influenza ) Uncontrolled psychotic condition Informed consent obtain Fertile woman want use effective contraception administration study drug Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>